Furthermore, in severe combined immunodeficient mice (SCID) mice injected with BALB/C CD4+ T cells, treatment with the GLP-1 agonist liraglutide alleviated colitis by significantly improving colon weight to length ratios, reducing histopathological score, and lowering pro-inflammatory cytokine levels such as CCL20, IL-33, and IL-22 [86]. This evidence concerns the gene GLP1R and colitis.